Similar articles

Abstract: With the number of cases of coronavirus disease-2019 (COVID-19) increasing rapidly, the World Health Organization (WHO) has recommended that patients with mild or moderate symptoms could be released from quarantine without nucleic acid retesting, and self-isolate in the community. This may pose a potential virus transmission risk. We aimed to develop a nomogram to predict the duration of viral shedding for individual COVID-19 patients. This retrospective multicentric study enrolled 135 patients as a training cohort and 102 patients as a validation cohort. Significant factors associated with the duration of viral shedding were identified by multivariate Cox modeling in the training cohort and combined to develop a nomogram to predict the probability of viral shedding at 9, 13, 17, and 21 d after admission. The nomogram was validated in the validation cohort and evaluated by concordance index (C-index), area under the curve (AUC), and calibration curve. A higher absolute lymphocyte count (P=0.001) and lymphocyte-to-monocyte ratio (P=0.013) were correlated with a shorter duration of viral shedding, while a longer activated partial thromboplastin time (P=0.007) prolonged the viral shedding duration. The C-indices of the nomogram were 0.732 (95% confidence interval (CI): 0.685‒0.777) in the training cohort and 0.703 (95% CI: 0.642‒0.764) in the validation cohort. The AUC showed a good discriminative ability (training cohort: 0.879, 0.762, 0.738, and 0.715 for 9, 13, 17, and 21 d; validation cohort: 0.855, 0.758, 0.728, and 0.706 for 9, 13, 17, and 21 d), and calibration curves were consistent between outcomes and predictions in both cohorts. A predictive nomogram for viral shedding duration based on three easily accessible factors was developed to help estimate appropriate self-isolation time for patients with mild or moderate symptoms, and to control virus transmission.

构建并验证一个可以预测非重症新型冠状病毒肺炎（COVID-19）患者病毒脱落（核酸转阴）时长的列线图

[1]BullardJ, DustK, FunkD, et al., 2020. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis, 71(10):2663-2666.

[2]ChenRC, LiangWH, JiangM, et al., 2020. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest, 158(1):97-105.

[3]DeLongER, DeLongDM, Clarke-PearsonDL, 1988. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 44(3):837-845.

[4]Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention, 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol, 41(2):145-151 (in Chinese).

[5]GiannisD, ZiogasIA, GianniP, 2020. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol, 127:104362.

[6]GuanWJ, NiZY, HuY, et al., 2020. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 382(18):1708-1720.

[7]HenryBM, de OliveiraMHS, BenoitS, et al., 2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med, 58(7):1021-1028.

[8]LiG, FanYH, LaiYN, et al., 2020. Coronavirus infections and immune responses. J Med Virol, 92(4):424-432.

[9]LiLZ, ZhangBH, HeB, et al., 2020. Critical patients with coronavirus disease 2019: risk factors and outcome nomogram. J Infect, 80(6):e37-e38.

[10]LiQ, GuanXH, WuP, et al., 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 382(13):1199-1207.

[11]LianJS, CaiH, HaoSR, et al., 2020. Comparison of epidemiological and clinical characteristics of COVID-19 patients with and without Wuhan exposure history in Zhejiang Province, China. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(5):369-377.

[12]LiangWH, LiangHR, OuLM, et al., 2020. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med, 180(8):1081-1089.

[13]LinAF, HeZB, ZhangS, et al., 2020. Early risk factors for the duration of severe acute respiratory syndrome coronavirus 2 viral positivity in patients with coronavirus disease 2019. Clin Infect Dis, 71(16):2061-2065.

[14]NHC (National Health Commission of the People’s Republic of China), 2020. Clinical diagnosis and treatment guidance of 2019 novel coronavirus (2019-nCoV) caused pneumonia (5th Edition). http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440/files/7260301a393845fc87fcf6dd52965ecb.pdf(in Chinese).

[15]SubramaniamS, ScharrerI, 2018. Procoagulant activity during viral infections. Front Biosci (Landmark Ed), 23:1060-1081.

[16]SunSY, CaiXJ, WangHG, et al., 2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta, 507:174-180.

[17]TangN, LiDJ, WangX, et al., 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 18(4):844-847.

[18]WHO (World Health Organization), 2020a. Clinical management of COVID-19: interim guidance. https://www.who.int/publications/i/item/clinical-management-of-covid-19

[19]WHO, 2020b. Coronavirus disease (COVID-19): situation reports-209. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200816-covid-19-sitrep-209.pdf?sfvrsn= 5dde1ca2_2

[20]WHO, 2020c. Criteria for releasing COVID-19 patients from isolation. https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation

[21]WHO, 2020d. Laboratory testing of human suspected cases of novel coronavirus (nCoV) infection: interim guidance. https://apps.who.int/iris/bitstream/handle/10665/330374/WHO-2019-nCoV-laboratory-2020.1-eng.pdf

[22]WölfelR, CormanVM, GuggemosW, et al., 2020. Virological assessment of hospitalized patients with COVID-2019. Nature, 581(7809):465-469.

[23]WuCM, ChenXY, CaiYP, et al., 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, 180(7):934-943.

[24]XiaoAT, TongYX, ZhangS, 2020. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis, 71(16):2249-2251.

[25]XuKJ, ChenYF, YuanJ, et al., 2020. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis, 71(15):799-806.

[26]YangAP, LiuJP, TaoWQ, et al., 2020. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol, 84:106504.

[27]YangY, ShenCG, LiJX, et al., 2020. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol, 146(1):119-127.e4.

[28]ZhaoQW, MengM, KumarR, et al., 2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis, 96:131-135.

[29]ZhengHY, ZhangM, YangCX, et al., 2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol, 17(5):541-543.

[30]ZhengSF, FanJ, YuF, et al., 2020. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January‒March 2020: retrospective cohort study. BMJ, 369:m1443.

[31]ZhouF, YuT, DuRH, et al., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395(10229):1054-1062.

[32]ZhouYG, FuBQ, ZhengXH, et al., 2020. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Nat Sci Rev, 7(6):998-1002.

[33]ZhouZ, RenLL, ZhangL, et al., 2020. Overly exuberant innate immune response to SARS-CoV-2 infection. SSRN, in press.

[34]ZhuN, ZhangDY, WangWL, et al., 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 382(8):727-733.

[35]ZouL, RuanF, HuangM, et al., 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med, 382(12):1177-1179.